asked Her Majesty's Government:How many adults with haemophilia in England are currently receiving (a) plasma-derived haemophilia treatment products and (b) recombinant treatment products; and [HL579]What would be the additional cost to the National Health Service of treating with recombinant genetically engineered products all adults with haemophilia in England currently receiving plasma treatment products. [HL580]
Based on figures provided by the United Kingdom Haemophilia Centre Doctors Organisation, we estimate that approximately 13 per cent of adult haemophilia A patients and 4 per cent of haemophilia B patients in England are currently receiving recombinant clotting factors. We estimate that the additional cost of providing all adult haemophilia patients with recombinant clotting factors at around £50 million per annum.
asked Her Majesty's Government:What differences exist between the provision of recombinant genetically engineered haemophilia treatment product in England, Scotland, Wales and Northern Ireland; and [HL581]Further to the Written Answer by Lord Hunt of Kings Heath on 29 January on haemophilia patients and vCJD in blood products (
WA 37), whether all adults with haemophilia in England will in future be treated with recombinant genetically engineered treatment products, as is provided for children under 16 in England and all haemophilia patients in Scotland, Wales and Northern Ireland. [HL582]
In England, all new haemophilia patients and children under 16 are treated with recombinant clotting factors. Scotland, Wales and Northern Ireland provide, or are in the process of providing, recombinant clotting factors for all haemophilia patients. The Government are currently considering whether all adult haemophilia patients in England should also be treated with recombinant clotting factors.